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Perry Elliott, MBBS, MDSEE PAGE 2765R estrictive cardiomyopathy offers a goodexample of a medical controversy that neverseems to lessen in spite of frequent and
sometimes passionate debate. For decades, its very
existence as a discrete entity has been questioned
on the basis that its deﬁning feature—so called
“restrictive physiology”—is shared by disorders with
very different causes and prognosis. However, for
many clinicians, the term provides a useful label for
a group of rare diseases in which severe diastolic
dysfunction is the primary cause of symptoms. For
the purposes of this editorial, I use the term restric-
tive cardiomyopathy to describe a group of heart
muscle disorders characterized by increased myocar-
dial stiffness that causes intraventricular pressure to
rise steeply with small increases in volume in the
presence of normal or decreased diastolic left ventric-
ular volumes and wall thickness (1).
When deﬁned in this manner, restrictive cardio-
myopathy becomes the least frequent cardiomyo-
pathy subtype. It is often stated that restrictive
cardiomyopathy in adults and children is usually
idiopathic, with a small proportion caused by inﬁl-
trative and metabolic disorders; however, once
amyloidosis is excluded (another source of debate
because it is typically characterized by myocardial
thickening and therefore excluded by current deﬁni-
tions of restrictive cardiomyopathy), most contem-
porary series suggest that familial or genetic disease
is frequent, particularly in children (2–4).
As in all other cardiomyopathies, the genetic
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Z-disk genes lead the list, followed by genes encoding
proteins such as desmin or mitochondrial DNA
(3,4). The molecular basis of abnormal diastolic ven-
tricular function in most genetic forms of restrictive
cardiomyopathy remains unknown but is very likely
related to the effect of individual mutations on the
proteins and regulatory pathways involved in acto-
myosin cross-bridge cycling. In some circumstances,
abnormalities of the cardiac interstitium may also
contribute to and perhaps dominate the clinical
picture.
Striated muscle myoﬁbrils are composed of a
network of cytoskeletal proteins and regulatory mol-
ecules whose interactions are necessary for myocyte
contraction. The major elements of these networks
are the sarcomeres, which are composed of precisely
aligned thick (myosin) and thin (actin) ﬁlaments,
and a third protein complex formed by the giant
polypeptide titin. Titin plays a major role in deter-
mining the mechanical properties of the heart
through its effects on passive tension during myo-
cardial stretch and restoring forces during early ven-
tricular ﬁlling and is an important biomechanical
sensor and organizational element within the sarco-
mere (5,6).In this issue of the Journal, Huby et al. (7) studied
the molecular basis of restrictive cardiomyopathy
caused by a previously reported mutation in the
myopalladin (MYPN) gene, which encodes a 147-kDa
multifunctional protein. Myopalladin is found at the
Z- and I-bands of the sarcomere and sometimes in the
nucleus of cardiac and skeletal myocytes. At the
Z-disk, myopalladin forms a complex with alpha-
actinin and nebulette (or nebulin in skeletal muscle)
that tethers actin and titin, whereas its N-terminal
domain binds cardiac ankyrin repeat protein (CARP).
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2778Involved in the control of muscle gene expression,
CARP is an early differentiation marker of cardiac
myogenesis expressed during embryonic and fetal
heart development and in end-stage heart failure (8).
It is thought that CARP shuttles between the cytosolic
and nuclear compartments to convert titin ﬁlament–
based strain signals into transcriptional responses.
Recently, mutations in the MYPN and CARP-
encoding ANKRD1 genes have been reported in
patients with dilated, hypertrophic, and restrictive
cardiomyopathy (8–11). Using a combination of func-
tional tests, cardiac histology, and molecular genetic
studies, Huby et al. (7) studied the effects of a muta-
tion in MYPN—Q526X—in the heart of a knock-in het-
erozygote and homozygote mouse model. In the
heterozygous form, signs of diastolic dysfunction with
preserved systolic function developed by 12 weeks,
together with interstitial and perivascular ﬁbrosis but
not hypertrophic remodeling. The truncated MYPN-
Q526X protein was found to translocate to the nu-
cleus, and levels of total and nuclear CARP were
reduced. This reduction in nuclear CARP expression
was associated with alterations in the downstream
extracellular signal–regulated kinase (ERK) cascade,
thought to be important in the regulation of stretch
signaling at the Z-disk, and increases in the expression
of ﬁbrotic, inﬂammatory, and antiapoptotic genes.
The authors concluded that the restrictive cardio-
myopathy phenotype in this model was caused by
persistence of the truncated mutant MYPN-Q526X
protein in the nucleus, which caused a reduction
in CARP expression. Although the role of muscle
ankyrin repeat proteins is far from clear (12), this
study underscores the pathogenicity of truncatedCARP and supports a nuclear regulatory role of the
protein.
In addition to conﬁrming the importance of myo-
palladin to the functional integrity of the sarcomere,
this study also opens a window on the possible
future treatment of rare cardiomyopathies. As the
researchers observed, conventional heart failure
drugs such as angiotensin-converting enzyme in-
hibitors are often unhelpful or of limited use in pa-
tients with heart muscle disease of genetic origin,
and we urgently need new strategies that can correct
the molecular pathology of individual diseases.
Achieving this ambition will, of course, not be a
trivial undertaking, particularly in autosomal domi-
nant diseases, for which the goal is not only to
restore a level of normally functioning transcript or
protein but also to suppress the effect of poison
peptides. Nevertheless, a growing number of studies
are exploring methods of correcting the adverse
consequences of genetic mutations, including exon
skipping, RNA interference, and the modulation of
gene expression through the delivery into cells of
genetic material in the form of DNA, noncoding RNA,
or oligonucleotides. Enormous effort and monies are
being invested in the pursuit of niche therapies for
rare cancers and blood disorders; the hope is that
studies such as this one from Huby et al. (7) also will
stimulate the search for new treatments in rare car-
diovascular diseases.
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